Interferon
As of the edition of 20 October 2026, Interferon is a protein: marketed, first approved in 1995 (CH); acts on IFNAR1 and IFNAR2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1995
- Kind
- Protein
- Brand name
- Betaferon
- First approved
- 29 August 1995 (CH)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Bayer
- Registered trials
- 44, 7 stopped early
- Disease areas
- Cancer; Digestive system; Infections; Immune system; Blood and lymph; Urinary and reproductive
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 12 | 5 | 0 | 0 |
| Phase 1 | 3 | 2 | 0 | 1 |
| Phase 2 | 20 | 12 | 1 | 4 |
| Phase 3 | 5 | 2 | 1 | 0 |
| Phase 4 | 4 | 1 | 1 | 2 |
| All trials | 44 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Bayer | Applicant and Lead sponsor of trials | 1995 to now |